Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Baxdrostat - CinCor Pharma

Next Previous
Drug Profile

Baxdrostat - CinCor Pharma

Alternative Names: CIN-107

Latest Information Update: 13 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Roche
  • Developer AstraZeneca; CinCor Pharma; CinRx Pharma
  • Class Amides; Antihypertensives; Antisecretories; Isoquinolines; Small molecules
  • Mechanism of Action Cytochrome P-450 CYP11B2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Hyperaldosteronism; Hypertension; Renal failure
  • No development reported Spinal cord disorders

Most Recent Events

  • 08 Oct 2025 Efficacy and adverse events data from a phase III trial in Hypertension released by AstraZeneca
  • 30 Aug 2025 Efficacy and adverse events data from phase III trial in Hypertension releases by AstraZeneca
  • 17 Aug 2025 AstraZeneca completes phase-III clinical trials in Hypertension (Treatment-resistant) in US, Canada, Turkey, the UK and may expand to Argentina, Australia, Belgium, Bulgaria, Czech Republic, Germany, Greece, Hungary, Malaysia, Philippines, Poland, Saudi Arabia, Slovakia, South Africa, Spain, Taiwan, Thailand, Vietnam (PO) (NCT06168409)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top